Effects of Rosemary Essential Oil on Human Cognition (Rosmarinus)
28 de abril de 2026 atualizado por: Heloisa de Freitas Pacífico, Federal University of Paraíba
The Use of Rosmarinus Officinalis L. Essential Oil (Camphor and Cineol Chemotypes) in Cognition: a Randomized, Double-blind, Placebo-controlled Study
Aromatherapy is one of the complementary therapies that is carried out through essential oils.
The essential oil of Rosmarinus Officinalis L. (rosemary) has been gaining attention in aromatherapy research, as studies have shown that the use of this oil is one of the promising non-pharmacological therapies for cognition.
In this way, inhalation of rosemary essential oil is one of the forms of cognitive intervention across different age groups.
The study will aim to analyze the effect of rosemary essential oil, with the following chemotypes: camphor and cineole, on the cognitive performance of adults.
Significant differences are expected between the control (placebo) and experimental groups, given that studies in humans have already shown significant effects of rosemary essential oil on cognition.
Considering the inclusion and exclusion criteria of the study, participants will be allocated to either the control or experimental group.
Consequently, the application of the tests will be carried out neuropsychological tests for the pre-test evaluation, followed by aromatherapy (acute phase) and the reapplication of the tests (post-test phase 1).
For 14 days, the participants will chronically use rosemary essential oil and at the end they will participate in the reapplication of the neuropsychological tests (post-test phase 2).
For inferential analyses, the ANOVA test or its non-parametric equivalent will be used.
In addition, linear regressions may be performed to verify how much the essential oil can predict the outcome of the study's dependent variables.
Effect Size will also be calculated.
Keywords: Chronic intervention; neuropsychology; aromatherapy.
Visão geral do estudo
Status
Ativo, não recrutando
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
63
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Paraíba
-
João Pessoa, Paraíba, Brasil, 58062-106
- Helô
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Sim
Descrição
Inclusion Criteria:
- 1a Healthy adults
- 1b should be able to inhale the essential oil
Exclusion Criteria:
- 2a Neurodegenerative diseases
- 2b Traumatic brain injury
- 2c Brain tumors
- 2d Multiple sclerosis
- 2e Epileptic seizures
- 2f Anxiety Disorder
- 2g Depressive Disorders,
- 2h Uncontrolled arterial hypertension,
- 2i nutritional deficiency or thyroid disease.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: essential oil of Rosmarinus officinalis 1
Inhalation of 2 drops of rosemary camphor essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
|
Sem intervenção: Placebo
Inhalation of 2 drops of sunflower essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
|
|
Comparador Ativo: essential oil of Rosmarinus officinalis 2
Inhalation of 2 drops of rosemary cineol essential oil for 5 minutes, for once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
STROOP TEST
Prazo: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Unit of measurement: time (seconds)
|
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subteste Digits of the Test WAIS-III - (Wechsler Adult Scale)
Prazo: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1a. Maximum raw score: 30 1b. Minimum raw score: 2 |
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subtest Number and Letter Sequence of the WAIS-III Test - (Wechsler Adult Scale)
Prazo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 21 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Tower of London
Prazo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 46 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Token Test
Prazo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 36 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Corsi Blocks
Prazo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 30 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Hopkins Verbal Learning
Prazo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 0 1b. Minimum raw score: 36 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de março de 2025
Conclusão Primária (Estimado)
1 de dezembro de 2026
Conclusão do estudo (Estimado)
31 de dezembro de 2026
Datas de inscrição no estudo
Enviado pela primeira vez
13 de abril de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
28 de abril de 2026
Primeira postagem (Real)
1 de maio de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
1 de maio de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
28 de abril de 2026
Última verificação
1 de abril de 2026
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- 80434324.0.0000.5188
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .